The effect of melanotropin release inhibiting factor, its metabolites and analogs on [ 3H]spiroperidol and [ 3H]apomorphine binding sites

Abstract

1. 1. The effects of melanotrophin release inhibiting factor (Pro-Leu-Gly-NH 2, MIF), its possible metabolites, Pro-Leu-OH, Leu-Gly-NH 2, Leu-Gly-OH and an analogue, cyclo(Leu-Gly), on [ 3H]spiroperidol binding sites in the striatum and on [ 3H]apomorphine binding sites in the striatum and hypothalamus of male Sprague-Dawley rats were determined. 2. 2. [ 3H]Spiroperidol binding to dopamine receptors in striatal membranes was unaffected by any of the above peptides in concentration up to 0.1 mM. 3. 3. The binding of [ 3H]apomorphine was enhanced by MIF, Pro-Leu-OH and cyclo(Leu-Gly) in both striatal and hypothalamic membranes in submicromolar concentrations. Leu-Gly-NH 2 and Leu-Gly-OH did not affect [ 3H]apomorphine binding to dopamine receptors in striatum of hypothalamus. 4. 4. The enhancement in binding of [ 3H]apomorphine by MIF and cyclo(Leu-Gly) was not related to the changes in the number of binding sites but to an increase in the affinity to the receptors. 5. 5. The results indicate that MIF and some of its related peptides do not affect dopamine receptor binding sites labeled by the neuroleptic [ 3H]spiroperidol but facilitate the transmission in those sites labeled by [ 3H]apomorphine. Since [ 3H]apomorphine and [ 3H]spiroperidol predominantly label pre- and post-synaptic dopamine receptors, it is concluded that MIF and its active analogs interact with presynaptic dopamine receptors.